Pulmonary impairment following respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients

Hematopoietic cell transplantation (HCT) is an important curative option for many refractory and high-risk malignancies [1]. Respiratory viral infections (RVIs) are increasingly recognized as important causes of morbidity and mortality in the general population [2], and are particularly common after HCT [3,4]. Depending on the viral species, more than 30% of RVIs in HCT recipients progress to lower respiratory tract infections (LRIs) [3], resulting in high mortality [5-9]. About 30% of allogeneic HCT (allo-HCT) recipients develop LRI after respiratory syncytial virus (RSV) infection, and the overall mortality rate after RSV infection is about 16% [10].

Source: Biology of Blood and Marrow Transplantation - December 3, 2018 Category: Hematology Authors: Ajay Sheshadri, Roy F. Chemaly, Amin M. Alousi, Pankil K. Shah, Gabriela Rondon, Lara Bashoura, Joumana Kmeid, Jacques Azzi, David W. Blanco, Maryam Kaous, Burton F. Dickey, Richard E. Champlin, Dimpy P. Shah Source Type: research